Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-DR4/TRAIL R1 Antibody-PE (6F81) is a PE-conjugated Mouse antibody targeting DR4/TRAIL R1. Anti-DR4/TRAIL R1 Antibody-PE (6F81) can be used in FCM.
Description | Anti-DR4/TRAIL R1 Antibody-PE (6F81) is a PE-conjugated Mouse antibody targeting DR4/TRAIL R1. Anti-DR4/TRAIL R1 Antibody-PE (6F81) can be used in FCM. |
Ig Type | Monoclonal Mouse IgG1 |
Clone | 6F81 |
Reactivity | Human |
Verified Activity | Flow cytometric analysis of human TNFRSF10A(CD261) expression on HeLa cells. HeLa cells were stained with PE-conjugated anti-Human TNFRSF10A(CD261). The histogram were derived from gated events with the forward and side light-scatter characteristics of intact cells. |
Application | FCM |
Recommended Dose | 10 μl/Test, 0.1 mg/ml |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human TRAIL R1 / CD261 / TNFRSF10A (rh TRAIL R1 / CD261 / TNFRSF10A; TMPY-01720; NP_003835.2; Met1-Asn239) and conjugated with PE under optimum conditions, the unreacted PE was removed. |
Purification | Protein A |
Appearance | Liquid |
Formulation | PBS solution containing 0.5% BSA and 0.09% sodium azide |
Research Background | Tumor necrosis factor receptor superfamily, member 10a (TRAIL R1), also known as TRAIL receptor 1 (TRAIL R1) or CD261 antigen, is a member of the TNF-receptor superfamily. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL), and thus transduces cell death signal and induces cell apoptosis. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. TRAIL R1/CD261/TNFRSF10A serves as a receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. TRAIL R1 can promote the activation of NF-kappa-B. TRAIL R1/CD261/TNFRSF10A induces apoptosis of many transformed cell lines but not of normal tissues, even though its death domain-containing receptor, DR4, is expressed on both cell types.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
Conjucates | PE |
Others Formats | Unconjugated/FITC |
Antibody Types Available | 3 |
Immunogen | Recombinant Human TRAIL R1 / CD261 / TNFRSF10A protein (TMPY-01720) |
Antigen Species | Human |
Biology Area | Cancer Drug Targets |
Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.